TRIDENT LIFELINE
|
The Current P/E Ratio of TRIDENT LIFELINE is 39.08.
Share Price | ₹270.0 | Jul 03,2025 |
Market Cap | ₹313.2 Cr | |
Earnings-TTM | ₹8.0 Cr | TTM-Consolidated Results |
Price/Earnings | 39.08x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of TRIDENT LIFELINE
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹313.2 Cr] as on Jul 03,2025
(/) Earnings [ ₹8.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 39.08x ]
Thus, for TRIDENT LIFELINE , the investors are currently willing to pay 39.08 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of TRIDENT LIFELINE !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of TRIDENT LIFELINE over the last five years.
Historical PE (Price/Earnings) ratio chart of TRIDENT LIFELINE
PE Ratio Performance Analysis for TRIDENT LIFELINE
- TRIDENT LIFELINE 's p/e ratio for fiscal years ending Mar2024 to Mar2022 averaged 20.04x.
- TRIDENT LIFELINE 's operated at median p/e ratio of 29.71x from fiscal years ending March 2018 to 2022.
- Looking back at the last 3 fiscal years, TRIDENT LIFELINE 's p/e ratio peaked in Mar2023 at 30.41x.
- TRIDENT LIFELINE 's p/e ratio hit its five-year low in Mar2022 of 0x.
How does TRIDENT LIFELINE 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
TRIDENT LIFELINE | 8.01 | 39.08 | 313.2 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,980.10 | 36.68 | 402,788.0 |
DIVIS LABORATORIES LTD | 2,191.00 | 83.20 | 182,283.0 |
CIPLA LTD | 5,291.05 | 23.03 | 121,853.0 |
TORRENT PHARMACEUTICALS LTD | 1,911.00 | 59.09 | 112,914.0 |
DR REDDYS LABORATORIES LTD | 5,703.50 | 18.92 | 107,932.0 |
MANKIND PHARMA LTD | 2,003.22 | 48.70 | 97,548.4 |
ZYDUS LIFESCIENCES LTD | 4,614.80 | 21.79 | 100,563.0 |
LUPIN LTD | 3,306.26 | 27.01 | 89,315.4 |
AUROBINDO PHARMA LTD | 3,515.26 | 19.09 | 67,114.5 |
ABBOTT INDIA LTD | 1,414.44 | 53.31 | 75,397.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs TRIDENT LIFELINE 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.92x |
Max industry PE | 83.20x |
Median industry PE | 36.68x |
Average industry PE | 39.08x |
You may also like the below Video Courses